Trial
NCT00975806
Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Celgene
Collaborators
—
Condition
Renal Cell Carcinoma
Intervention
Lenalidomide
Why stopped
MTD determined sub-optimal as efficacious treatment for renal cell carcinoma.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-11-25